[Mupirocin: prophylaxis of hospital-acquired infections due to Staphylococcus aureus and sanitation of hospital environment].
Clinical efficacy of mupirocin ointment (dermatic and nasal) was evaluated in the treatment of oncologic patients with nosocomial infections of the staphylococcal etiology and carriers of S.aureus among the medical personnel. The use of dermatic ointment of mupirocin, a local antibiotic, in the treatment of the inpatients with nosocomial infections of the staphylococcal etiology allowed to lower at least 2.5 times the number of the prescriptions of vancomycin, a systemic antibiotic. The use of mupirocin nasal ointment provided absolute eradication of S.aureus strains in the carriers. Recolonization of the nasal passages with S.aureus in some carriers started only 3 months after the eradication. A 6-month observation of the carriers after the sanitation showed that the recolonization frequency by the end of the observation period amounted to 19%. A prolonged for more than 4 months effect of the treatment with mupirocin was stated in 81% of the cases. The monitoring of S.aureus circulation in the intrahospital environment revealed that its level during that period was 6 times lower than the initial one which was obviously due to the use of mupirocin (dermatic and nasal) for the carrier sanitation and the patient treatment.
Mitrokhin
S D
SD
Municipal Clinical Oncologic Hospital No. 62, Moscow.
D000281:Administration, Intranasal; D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002353:Carrier State / Q000517:prevention & control; D003428:Cross Infection / Q000188:drug therapy* / Q000517:prevention & control* / Q000635:transmission; D004334:Drug Administration Schedule; D004784:Environmental Monitoring; D006801:Humans; D017757:Infectious Disease Transmission, Professional-to-Patient / Q000517:prevention & control*; D008505:Medical Staff, Hospital; D016712:Mupirocin / Q000008:administration & dosage / Q000627:therapeutic use*; D009824:Ointments / Q000627:therapeutic use; D011322:Primary Prevention; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000517:prevention & control* / Q000635:transmission; D013997:Time Factors
D000900:Anti-Bacterial Agents; D009824:Ointments; D016712:Mupirocin